^
Association details:
| Biomarker: | Chr del(20q) + ASXL1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | azacitidine (DNMT inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
3099 Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1 Chromosomal Deletion and Genetic Mutations
Published date:
11/04/2020
Excerpt:
In MDS patients with del(20q), the alteration of ASXL1 by chromosome deletion or somatic mutation was associated with adverse clinical features and a poorer response to AZA. Its detection at diagnosis would allow the rapid identification of a subgroup of MDS patients with a poor prognosis that could benefit of earlier and more effective therapies.
